@ashleymoodyfl Please increase research funding for Alzheimer's and dementia research activities at the NIH by an additional $113.485 million in FY26 and provide $35 million to continue funding the implementation of the BOLD Infrastructure for Alzheimer’s Act at the CDC.
@michellefischb Please increase research funding for Alzheimer's and dementia research activities at the NIH by an additional $113.485 million in FY26 and provide $35 million to continue funding the implementation of the BOLD Infrastructure for Alzheimer’s Act at the CDC.
Earlier today, the Senate unanimously passed the bipartisan #BOLDAlzheimersAct 🎉 This critical bill is now going to the president’s desk to be signed into law. Read more about the bold steps our advocates & congressional champions took to get us here: https://t.co/o1VRib161R
.@RepFischbach please pass the NAPA Reauthorization Act of 2023 and the Alzheimer's Accountability and Investment Act. It’s time to renew our nation’s commitment to addressing Alzheimer’s disease by building on the National Alzheimer’s Plan.
Tell Congress to stick to the plan and keep Alzheimer’s and dementia a national priority by supporting the #NAPAAct and #AlzInvestmentAct: https://t.co/MLINS0uWX6.
In 2024, we're asking #mnleg to:
- Create a dementia programs manager position at MDH
- Make caregiver respite more affordable/available
- Create a dementia curriculum for high school students
- Support dementia risk reduction in communities of color https://t.co/e1ZlOu3z85
Thank you @RepFischbach for seeking improved dementia care management solutions and working with @CMSGov to advance the GUIDE Model, an innovative test initiative. #AlzCareAct#ENDALZ https://t.co/J65mlutUxQ
Thank you @SenAmyKlobuchar@SenTinaSmith for your support to streamline today's complicated health care maze for people living with dementia and their caregivers. I appreciate your cosponsorship of the #AlzCareAct#ENDALZ https://t.co/J65mlutUxQ
In April 2022, the Centers for Medicare & Medicaid Services (CMS) issued an unprecedented decision that blocks Medicare coverage of FDA-approved treatments for Alzheimer's disease. This decision must be reversed.
Take action at https://t.co/LTeL48SYjz. https://t.co/KAs29mCd9M
In April 2022, the Centers for Medicare & Medicaid Services (CMS) issued an unprecedented decision that blocks Medicare coverage of FDA-approved treatments for Alzheimer's disease. This decision must be reversed.
Take action at https://t.co/LTeL48SYjz. https://t.co/KAs29mCd9M
People with Alzheimer’s deserve #MoreTime with their loved ones, but CMS is preventing that by blocking access to FDA-approved treatments. Ask @SecBecerra to end this policy. @RepFischbach
Thank you Meghan at Congresswoman @FischbachMN7’s office for listening today. We look for your support to give #moretime to those living with Alzheimer’s by contacting CMS to reconsider their decision of discrimination against those living with Alzheimer’s.
#ENDALZ#alzforum